| Name | Title | Contact Details |
|---|
Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
Bioo Scientific is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CNS Therapeutics is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.